Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial

Clinical Immunology

Volumn 90, Issue 1, 1999, Pages 100-107

  Boyer, Jean D ^a   Chattergoon, Michael A ^a   Ugen, Kenneth E ^b   Shah, Ami ^a   Bennett, Mosi ^a   Cohen, Adam ^a   Nyland, Susan ^b   Lacy, Kim E ^c   Bagarazzi, Mark L ^d   Higgins, Terry J ^e   Baine, Yaela ^e   Ciccarelli, Richard B ^e   Ginsberg, Richard S ^e   MacGregor, Rob Roy ^c   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e WLVP   (United States)

Author keywords

DNA vaccines; HIV 1; Immunotherapy

Indexed keywords

ANTIRETROVIRUS AGENT; DNA VACCINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MEASLES MUMPS RUBELLA VACCINE; RANTES;

ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; DRUG TOLERABILITY; ENVELOPE GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOPROPHYLAXIS; IMMUNOSTIMULATION; IMMUNOTHERAPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION; VIRUS LOAD;

EID: 0032937060     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1998.4616     Document Type: Article

References (46)

1. Pantaleo G., Menzo S., Vaccarezza M. Studies in subjects with long-term nonprogressive Human immunodeficiency virus infection. N. Engl. J. Med. 332:1995;209-216.
2. Haynes B. F., Panaleo G., Fauci A. S. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:1996;324-328.
3. Rinaldo C., Huang X., Fan Z. High levels of anti-HIV-1 memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J. Virol. 69:1995;5838-5842.
4. Borrow P., Lewicki H., Hahn B. H. Virus-specific CD8 cytotoxic T lymphocyte activity associated with control of viremia in primary human immunodefeciency virus type 1 infection. J. Virol. 68:1994;6103-6110.
5. Rowland-Jones S. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1:1995;59-64.
6. Rowland-Jones S., Nixon D., Aldhous M. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet. 341:1993;860-861.
7. Ugen K. E., Srikantan V., Goedert J. J., Nelson R. P., Williams W. V., Weiner D. B. Vertical transmission of Immunodeficiency Virus Type 1: Seroreactivity by maternal antibodies to the carboxy region of the gp41 envelope. J. Infect. Dis. 175:1997;63-69.
8. Ugen K. E., Goedert J. J., Boyer J. Vertical transmission of HIV infection. Reactivity of maternal sera with glycoprotein120 and 41 peptides from HIV type 1. J. Clin. Invest. 89:1992;1923-1930.
9. Rossi P., Moschese V., Broliden P. Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc. Natl. Acad. Sci. USA. 86:1989;8055-8058.
10. Goedert J., Mendez H., Drummond J. Mother-to-infant transmission of human immunodeficiency virus type 1: Association with prematurity or low anti-gp120. Lancet. 2:1989;1351-1354.
11. Rosenberg E. S., Billings J. M., Caliendo A. M. Vigorous HIV-1 Specific CD4 T cell responses associated with control of viremia. Science. 278:1997;1447-1450.
12. +. Science. 270:1995;1811-1815.
13. +. Immunology. 66:1989;628-630.
14. +in vitro. Science. 66:1989;1663-1566.
15. Mackewicz C. E., Ortega H. W., Levy J. A. CD8 activity correlates with the clinical state of the infected individual. J. Clin. Invest. 87:1991;1462-1466.
16. +. Science. 270:1996;1811-1815.
17. ++. Nat. Med. 3:1997;533-540.
18. Schluter, W. W. Kemper, C. A. Deresinski, S. C. et al., Immunogenicity and safety of measles vaccine among HIV-infected persons, 37th ICAAC, Toronto, Canada, 1997.
19. Belshe R. B., Clements M. L., Dolin R. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J. Infect. Dis. 168:1993;1387-1395.
20. Keefer M. C., Graham B. S., Belshe R. B. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. AIDS Res. Hum. Retro. 10:1994;1713-1723.
21. Schwartz D. H., Gorse G., Clements M. L. Induction of HIV-1 neutralizing and syncytium-inhibiting antibodies in uninfected recipients of HIV-1 IIIB rgp120 subunit vaccine. Lancet. 342:1993;69-73.
22. Belshe R. B., Graham B. S., Keefer M. C. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA. 272:1994;475-480.
23. Biselli R., Loomis L. D., Bono V. D., Burke D. S., Redfield R. R., Birx D. L. Immunization of HIV-infected patients with rgp160: Modulation of anti-rgp120 antibody spectrotype. J. AIDS. 7:1994;1016-1024.
24. Loomis L. D., Deal C. D., Kersey K. S., Burke D. S., Redfield R. R., Birx D. L. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160. J. AIDS. 10:1995;13-17.
25. VanCott T. C., Bethke F. R., Burke D. S., Redfield R. R., Birx D. L. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J. Immunol. 155:1995;4100-4110.
26. MacGregor, R. R. Boyer, J. D. Ugen, K. E. et al., First human trial of a DNA-based vaccine for treatment of HIV-1 infection: Safety and host response, JID.
27. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A., Sandstom E., Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1 infected patients. Lancet. 351:1998;1320-1325.
28. Dubensky T., Campbell B., Villarreal L. Direct transfection of viral and plasmid DNA into the liver of spleen of mice. Proc. Natl. Acad. Sci. USA. 81:1984;7529-7533.
29. Raz E., Wantanabe A., Baird S. M. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc. Natl. Acad. Sci. USA. 90:1993;4523.
30. Wolff J. A., Malone R. W., Williams P. Direct gene transfer into mouse muscle in vivo. Science. 247:1990;1465-1468.
31. Wang B. K., Ugen K. E., Srikantan V. Gene inoculation generates immune responses against HIV-1. Proc. Natl. Acad. Sci. USA. 90:1993;4156-4160.
32. Ulmer J. B., Donnelly J., Parker S. E. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
33. Tang D. C., Devit M., Johnston S. A. Genetic immunization is a simple method for eliciting an immune response. Nature. 356:1992;152-154.
34. Michel M. L., Davis H. L., Schleef M., Mancini M., Tiollais P., Whalen R. DNA-mediated immunization to the hepatitus B surface antigen in mice: Aspects of the humoral response mimic hepatitis B viral infection in humans. Proc. Natl. Acad. Sci. USA. 92:1995;5307-5311.
35. Lowrie C. B., Tascon R. E., Colston M. J., Silva C. L. Towards a DNA vaccine against tuberculosis. Vaccine. 12:1994;1537-1540.
36. Lu, S. Arthos, J. Montefiori, D. C. et al., Simian immunodeficiency virus DNA vaccine trial in macaques, 70, 3978, 3991, 1996.
37. Haynes J. R., Fuller D. H., Eisenbraun M. D., Ford M. J., Pertmer T. M. Accell particle-mediated DNA immunization elicits humoral, cytotoxic and protective responses. AIDS Res. Hum. Retrov. 10:1994;S43-S45.
38. Okuda K., Bukawa H., Hamajima K. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 Env and Rev gene products. AIDS Res. Hum. Retrov. 11:1995;933-943.
39. Wang B., Boyer J. D., Srikantan V. Induction of humoral and cellular immune responses to the Human immunodeficiency type 1 virus in non-human primates by in vivo DNA inoculation. J. Virol. 21:1995;102-112.
40. Boyer J. D., Wang B., Ugen K. In vivo protective anti-HIV immune responses in nonhuman primates through DNA immunization. J. Med. Primatol. 25:1996;242-250.
41. Boyer J. D., Ugen K. E., Chattergoon M. DNA vaccination as anti-HIV immunotherapy in infected chimpanzees. J. Infect. Dis. 176:1997;1501-1509.
42. Boyer J. D., Ugen K. E., Wang B. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med. 3:1997;526-532.
43. Kim J. J., Ayyavoo V., Bagarazzi M. L. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J. Immunol. 158:1997;816-826.
44. Williams W. V., Fang Q., Von Feldt J. M. Immunotherapeutic strategies targeting rheumatoid synovial T-cell receptors by DNA inoculation. Immunol. Res. 13:1994;145-153.
45. Kim J. J., Bagarazzi M. L., Trivedi N. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat. Biotechnol. 15:1997;641-646.
46. Ogg G. S., Jin X., Bonhoeffer S. Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasm load of viral RNA. Science. 279:1998;2103-2106.